by Chatelain E, Don R. Antiparasitic Antibacterial Drug Discovery, April 2009, Paul M. Selzer (Ed), Wiley-Blackwell.
Summary: In answer to the lack of modern and effective drugs for diseases such as human African trypanosomiasis (HAT; sleeping sickness) and Chagas disease which present no financial viability for the pharmaceutical industry, new models of drug discovery have been developed.
The Drugs for Neglected Diseases initiative (DNDi) has adopted a model closely related to that of a virtual biotechnology company for identifying and optimizing drug leads.
